Global Market For SingleUse Technologies For Biopharmaceutical To Reach Nearly $2.4 Billion In 2017
12/04/2012

BCC Research is a leading publisher of market research reports and technical publications. Forthcoming report information can be found on our Web site at www.bccresearch.com

Online PR News – 04-December-2012 – Wellesley, MA – Wellesley, Mass. – According to a new technical market research report, SINGLE-USE TECHNOLOGIES FOR BIOPHARMACEUTICALS: GLOBAL MARKETS (BIO099A) from BCC Research (www.bccresearch.com), the global market for single-use technologies for biopharmaceuticals was valued at $720 million in 2011 and should reach $985.2 million in 2012. Total market value is expected to reach nearly $2.4 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 19.1%.

The market for single-use technologies for biopharmaceuticals biopharmaceuticals can be broken down into four regions: North America, Europe, Asia, and the rest of the world.

North America is expected to have a value of $344.9 million in 2012 and $710.5 million in 2017, a CAGR of 15.6%.

Europe should total $276 million in 2012 and $684.4 million in 2017, a CAGR of 19.9%.

The Asia market is expected to total $226.4 million in 2012 and $612.8 million in 2017, a CAGR of 22%.

As a segment, the rest of the world should total $137.9 million in 2012 and $354.4 million in 2017, a CAGR of 20.8%.

Single-use technologies are disposable or limited-use technologies used in the production and development of biopharmaceutical drugs. Bioproduction involves the handling of live organisms and requires cleaning and sterilization to eliminate contaminants. An active pharmaceutical ingredient must be extracted and purified before it is converted into a drug formulation. Materials used in clinical settings must also go through these procedures. Liquid and/or lyophilized forms of biomolecules are injectable and require quality checks similar to those performed for pharmaceuticals. Bioanalytical methods, such as ELISA or polymerase chain reaction (PCR), are also sometimes required.

Decisions regarding incorporation of the latest technology in the testing process of intermediates and final products are rather difficult to make; companies work closely with the FDA to meet quality and compliance requirements. An FDA publication lists the testing requirements for purified bulk and final drug products, cell banks and bioreactor harvests (i.e., “Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use”).

This report will help its readers:

• Forecast the market size for single-use technologies for biopharmaceuticals in terms of dollar and unit sales
• Classify the market size for single-use technologies for biopharmaceuticals by geographical regions in terms of dollar and unit sales
• Highlight the roles played by major stakeholders
• Provide an overview of the activities of influential companies
• Examine crucial, innovative breakthroughs by means of a detailed patent analysis.

This report will be valuable to many industry participants, including the following:

• Biopharmaceutical manufacturers
• Contract manufacturing organizations
• Single-use technology makers
• End users and distributors
• Academic and research institutions
• Financial institutions.